---
layout: default
title: Alfentanil Hcl
parent: 僅模型預測 (L5)
nav_order: 32
evidence_level: L5
indication_count: 0
---

# Alfentanil Hcl
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Alfentanil HCL: No TxGNN Repurposing Predictions Generated

---

## One-Sentence Summary

Alfentanil HCL is a short-acting synthetic opioid analgesic commonly used for analgesia and sedation during anaesthetic procedures.
The TxGNN model did not generate any repurposing predictions for this drug candidate in the current evidence pack.
As a result, no repurposing indication, clinical trial evidence, or literature evidence is available for evaluation at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not recorded in evidence pack |
| Predicted New Indication | No prediction generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction absent; no supporting studies |
| UK Market Status | Not recorded (0 licences in data) |
| Number of Marketing Authorisations | 0 (as per evidence pack) |
| Recommended Decision | **Hold** |

> ⚠️ **Data integrity note:** The evidence pack contains no UK marketing authorisation records for Alfentanil HCL and lists market status as "not marketed." This is inconsistent with known UK practice, where alfentanil (e.g., Rapifen®) holds MHRA authorisation for use in anaesthesia. The regulatory dataset should be verified before any further evaluation proceeds.

---

## Why is This Prediction Reasonable?

No repurposing prediction has been generated for Alfentanil HCL in this evidence pack, so a mechanism-based rationale for a new indication cannot be provided.

Currently, detailed mechanism of action data is not available in the evidence pack. Based on general pharmacological knowledge, Alfentanil HCL is a potent short-acting μ-opioid receptor agonist used principally as an analgesic adjunct in anaesthesia and procedural sedation. Its ultra-short duration of action and rapid onset make it distinct from other opioids in the same class.

Until TxGNN predictions are generated and MOA data is retrieved from DrugBank, no mechanistic bridge to a repurposed indication can be assessed.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for a repurposing indication, as no predicted indication has been generated.

---

## Literature Evidence

Currently no related literature available for a repurposing indication, as no predicted indication has been generated.

---

## UK Market Information

No marketing authorisation records are present in the current evidence pack.

> **Note for reviewers:** Alfentanil hydrochloride is a Schedule 2 Controlled Drug regulated under the Misuse of Drugs Regulations 2001 in the UK. Any repurposing pathway would require engagement with both MHRA and the Home Office. The DrugBank query on 27 March 2026 returned one result; however, the regulatory data fields were not populated. It is recommended to re-run the data pipeline with MHRA/OpenFDA lookups to populate this section.

---

## Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

> As Alfentanil HCL is a controlled opioid analgesic, particular attention should be paid to risks of respiratory depression, dependence, and interaction with CNS depressants when reviewing the SmPC. No safety data, contraindications, or drug–drug interaction records are present in this evidence pack.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The evidence pack for Alfentanil HCL is incomplete: no TxGNN repurposing predictions were generated, regulatory data is absent, MOA data is missing, and all safety fields contain data gaps. No meaningful repurposing evaluation can be conducted without resolving these blockers first.

**To proceed, the following is needed:**

- **[Blocking]** Re-run TxGNN prediction pipeline to generate candidate indications for Alfentanil HCL; confirm the drug is correctly mapped to its DrugBank ID before re-run
- **[Blocking]** Retrieve UK MHRA marketing authorisation records (Rapifen® and any generic alfentanil products) to populate the regulatory section
- **[High]** Retrieve MOA data from DrugBank API to support mechanism-of-action analysis
- **[High]** Retrieve SmPC warnings and contraindications (key safety data for a Schedule 2 opioid)
- **[Medium]** Confirm DrugBank ID mapping — the `drugbank_id` field is currently null despite a successful DrugBank query; investigate whether the query returned a match without extracting the ID
- **[Medium]** Clarify data pipeline input: `inputs_received` is empty in the meta block, suggesting the evidence pack may not have been correctly initialised with drug identifiers

---

*This report is for research purposes only and does not constitute medical advice. All repurposing candidates require clinical validation before any application to patient care. Suspected adverse reactions should be reported via the MHRA Yellow Card Scheme at [yellowcard.mhra.gov.uk](https://yellowcard.mhra.gov.uk).*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

